
Opinion|Videos|December 9, 2025
Examining a Novel FDA-approved Therapy in Desmoid Tumors
FDA approval of Nirogacistat for desmoid tumors highlights improved survival rates, quality of life, and manageable side effects for patients.
Advertisement
Episodes in this series

Panelists discuss the questions below in this video.
- What was the key
data that led to the FDA approval of nirogacestat in patients with desmoid tumors? How does its mechanism of action differ from other therapies? Can you describe thedata from the long-term study of nirogacestat? Why is this study valuable to clinicians? From your clinical experience, how has patient satisfaction been with nirogacestat? What has long-termdata demonstrated? What was found in studies that evaluated nirogacestat inpatient-reported outcomes andpain control? Ovarian toxicity was seen in the clinical trials in women treated with nirogacestat. What was theoutcome in these patients and is any intervention necessary?
Advertisement
Related to this article

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.

Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on AJMC
1
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
2
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
3
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MD
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5

